Abstract
Non small cell lung cancer is the illness with high mortality. It is the tumor with low sensitivity to chemotherapy and radiotherapy.
If the surgery is note indicated, the chance for long term survival is very low. In the Czech Republic, the surgery is real, at the time of diagnosis, in 10-17 % of patients.
Contrary do that, in our country, more than 50% of patients is diagnosed at the stage of locally advanced or metastatic disease, stage IIIB or IV. In this group of patients, 5-years survival reaches only 1%.
For non-resectable advanced or metastatic non small cell lung cancer, there is a consideration for the first line treatment of classic chemotherapy doublet with platinum based derivate with III. generation cytostatic (gemcitabin, vinorelbin, paclitaxel, docetaxel).